Owkin has raised $11 million. The startup will use the series A funds to scale its predictive analytics platform while working to form partnerships with major healthcare organizations.
New York-based Owkin’s first task is to bring Owkin Socrates to market. The product is pitched as a machine learning-enabled way to identify biomarker patterns in molecular data, image libraries and patient records. Owkin is aiming the product at drug discovery and development teams, plus hospital physician-researchers, and ultimately sees its range covering the full R&D and healthcare spectrum.
“Owkin’s comprehensive platform improves healthcare delivery by building algorithms that enable researchers and clinicians to analyze vast patient datasets and predict treatment outcomes in real time,” Bruno Raillard, partner at Owkin-investor Otium Venture, said in a statement. Raillard has joined the Owkin board.
The startup has gained access to 10 million documents on hundreds of thousands of patients from Institut Curie in Paris to support the development of the technology, Business Insider France reported. And it aims to start providing subscription-based access to the platform in about one year.
The series A moves Owkin closer to realizing this goal. Otium led the round with assists from Cathay Innovation, Plug and Play and NJF Capital. Owkin has earmarked the cash for the scaling of its technology and the pursuit of partnerships.
To date, Owkin has disclosed relationships with Amgen and Actelion. Thomas Clozel, M.D., the CEO and founder of Owkin, is the son of Jean-Paul Clozel, M.D., the cardiologist who cofounded Actelion and led it to a $30 billion takeover by Johnson & Johnson. The senior Clozel participated in Owkin’s seed round.